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A chemokine, monocyte chemoattractant protein 1 (MCP-1), attracts macrophages. The production of MCP-1 is enhanced in
keratinocytes of psoriatic lesions, which may contribute to macrophage infiltration into the lesions. It is known that estrogen
regulates the course of psoriasis. We examined in vitro effects of 17b-estradiol (E2) on MCP-1 production by human
keratinocytes. E2 inhibited constitutive and 12-O-tetradecanoylphorbol-13-acetate-induced MCP-1 secretion, mRNA expression,
and promoter activity in keratinocytes, and these effects of E2 were counteracted by estrogen receptor antagonist ICI 182 780.
GC-rich Spl element and activator protein 1 (AP-1) element on MCP-1 promoter were required for constitutive and 12-O-
tetradecanoylphorbol-13-acetate-induced transcription, respectively, and involved in transrepression by E2. E2 inhibited
constitutive Spl and 12-O-tetradecanoylphorbol-13-acetate-induced AP-1 transcriptional activities whereas it did not inhibit DNA
binding of Sp1 or AP-1 c-Fos/c-Jun. E2 inhibited Sp1 and AP-1 transcriptional activities and MCP-1 promoter activity in estrogen
receptor P (ERb) transfected SKBR3 cells. Deletion of the A/B region or mutation of activation function 2 in ERb abrogated E2-
dependent transcriptional inhibition by ERb whereas mutation of DNA-binding domain retained the inhibitory effects.
Transfection of ERb enhanced the inhibitory effects of E2 on Sp1 and AP-1 transcriptional activities andMCP-1 promoter activities
in nontransfected keratinocytes. Coimmunoprecipitation studies showed an E2-dependent association of ERb with Sp1 or AP-1
in ERb-transfected keratinocytes. These results suggest that E2-bound ERbmay inhibit MCP-1 gene expression by inhibiting Sp1
and AP-1 transcriptional activities in keratinocytes. A/B region and intact activation function 2 of ERbmay be responsible for the
effects of E2. Key words: AP-1/estrogen receptor/Sp1. J Invest Dermatol 120: 1058–1066, 2003
Psoriasis is characterized by epidermal hyperplasia associated with
vascular proliferation and inflammatory infiltrates (Bos and de Rie,
1999). Numerous macrophages arc accumulated in papillary dermis
of psoriatic skin lesions, which may be the source of proinflamma-
tory cytokines such as tumor necrosis factor a (TNF-a) or
interleukin-1 (IL-1) (Giustizieri et al., 2001). Monocyte chemoat-
tractant protein 1 (MCP-1) is thought to be a primary chemokine
attracting macrophages into psoriatic lesions (Gillitzer et al., 1993),
and may function as a mediator for acute and chronic inflammation
(Conti and DiGioacchino, 2001). It is reported that MCP-1
production by keratinocytes is increased in psoriatic skin lesions
(Gillitzer et al., 1993). Thus the blockage of MCP-1 production in
keratinocytes is a key therapeutic target for psoriasis.
It is reported that the natural course of psoriasis is modulated by
pregnancy (Farber and Nall, 1974; Dunna and Finlay, 1989; Boyd
et al., 1996), menstruation (Stevens et al., 1993; Boyd and King,
1999), or menopause (Mowad et al., 1998). These indicate the
modulatory role of sex hormones, especially estrogen, in the
pathogenesis of psoriasis. We recently found that 17b-cstradiol (E2)
acted on human keratinocytes and inhibited their interferon-g-
induced production of IP-10, which chemoattracts T helper 1 cells
(Kanda and Watanabe, 2003a). It is thus anticipated that E2 may
also inhibit MCP-1 production in human keratinocytes. The effects
of E2 on MCP-1 production have been studied in several other cell
types; however, the results arc conflicting: E2 inhibited lipopoly-
saccharide-induced JE/MCP-1 production in murine macrophages
in vitro (Frazier-Jessen and Kovacs, 1995) whereas it enhanced IL-1-
induced MCP-1 production in human endometrial cells in vitro
(Akoum et al., 2000) and MCP-1 production in murine splenocytes
in vivo (Matejuk et al., 2002). Thus the effects of E2 on MCP-1
production appear to differ depending on cell type or experimental
conditions. Precise mechanisms for the differential effects have not
been elucidated, however.
E2 exerts its effects via intracellular estrogen receptor (ER); E2-
bound ER upregulates or downregulates the transcription of various
genes by binding to estrogen response element of the target genes
(Beato, 1989) or by interacting with other transcription factors such
as activator protein 1 (AP-1) (Paech et al., 1997) or Sp1 (Safe, 2001).
ER exists as two subtypes, ERa and ERb, encoded by separate genes
(Mosselman et al., 1996; Mendelsohn and Karas, 1999). ERa and
ERb show overlapping and differential effects on gene expression.
We previously found that human keratinocytes express ERb but not
ERa (Kanda and Watanabe, 2003a, b), indicating that E2 exerts its
effects via ERb in keratinocytes.
In this study, we investigated in vitro effects of E2 on MCP-1
production in human keratinocytes. Full-length cDNA encoding
human MCP-1 has been cloned from human glioma cell lines
(Yoshimura et al., 1989). MCP-1 production can be induced by
proinflammatory cytokines such as TNF-a or phorbol esters such as
12-O-tetradecanoylphorbol-13-acetate (TPA) (Ueda et al., 1994).
TPA in vivo induces psoriasiform skin inflammation and epidermal
hyperplasia in mice (Reynolds et al., 1997), and in vitro induces
keratinocytes to express IL-8 (Barker et al., 1991a) or intercellular
adhesion molecule 1 (Griffiths et al., 1990), both of which are highly
related to the pathogenesis of psoriasis. In addition keratinocytes from
patients with psoriasis show extremely enhanced responses to TPA in
MCP-1 and IL-8 production compared to those from healthy controls
(Giustizieri et al., 2001). Thus TPA appears to be properly used as a
stimulus in the model system for MCP-1 production in psoriatic skin
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lesions. TPA mainly promotes the transcriptional activity of AP-1, and
the 50-flanking region in MCP-1 gene contains AP-1 binding sites
(Shyy et al., 1990). Although we found that E2 inhibited TNF-a or IL-1
(b-induced RANTES production in keratinocytes (Kanda and Wata-
nabc, 2003b), we have not examined the effects of E2 on TPA-
induced chemokine expression in keratinocytes. Thus in this study
we aimed to investigate whether E2 may alter TPA-induced MCP-1
production in keratinocytes. We found that E2 inhibited both
constitutive and TPA-induced MCP-1 production in keratinocytes at
transcriptional level. We further examined precise mechanisms for
the effects, focusing on E2-induced modulation of the activities of
transcription factors Sp1 and AP-1.
MATERIALS AND METHODS
Reagents
E2 and TPA were purchased from Sigma (St. Louis, MO). ICI 182 780 was from
Wako Pure Chemical Industries (Osaka, Japan). Antibodies used in the electro-
phorctic mobility shift assay (EMSA), immunoprecipitation, or western blot were
obtained from Santa Cruz Biotechnology (Santa Cruz, CA).
Culture of normal human epidermal keratinocytes
Human neonatal foreskin keratinocytes were cultured in serum-free kcratinocytc
growth medium (KGM) (Clonetics, Walkersville, MD) with 0.1mM of calcium ion,
consisting of basal medium MCDB153 supplemented with 0.5 pg per ml
hydrocortisone, 5 ng per ml epidermal growth factor, 5 pg per ml insulin, and
0.5% bovine pituitary extract. The cells in third passage were used for the
experiments.
Measurement of MCP-1 secretion
Keratinocytes (2 104 per well) were seeded in triplicate into 24-well plates in 1ml
KGM and adhered overnight, and then the medium was changed to basal KBM with
0.1mM of calcium ion depleted of phenol red, hormones, growth factors, and
bovine pituitary extract, and incubated for 24 h. At about 60% confluency, the
medium was removed and the cells were preincubated with E2 in phenol-red-free
KBM for 10min, and then incubated with TPA 10 nM in the presence or absence of
E2 for another 24 h. The supcrnatants were assayed for MCP-1 by enzyme-linked
immunosorbent assay (Biosourcc, Camarillo, CA). The sensitivity of the assay was
20 pg per ml.
Reverse transcription polymerase chain reaction (RT-PCR)
Keratinocytes were incubated as above for 6 h, and RNA was extracted using
mRNA purification kit (Pharmacia, Uppsala, Sweden) according to the manufac-
turer’s instruction. cDNA was made from RNA samples as described previously
(Tjandrawinata et al., 1997). Primers for amplification and the sizes of respective
PCR products were as follows: MCP-1, 50-CCCAGGGGTAGAACTGTGGTTCAA-30
(sense) and 50-CTGGCTCAGCCAGATGCAATCAAT-30 (antisense) for 480 bp
(Jedrzkicwicz et al., 1999); glyccraldchydc-3-phosphate dehydrogenase (GAPDH),
50-CCACCCATGGCAAATTCCATGGCA-30 (sense) and 50-TCTACACGGCAGGT-
CAGGTCCACC-30 (antisense) for 600 bp (Hu et al., 1999). PCR was performed by
one denaturing cycle of 95 1C for 3minutes, 30 cycles of denaturation at 95 1C for
30 seconds, annealing at 58 1C for 30 seconds, extension at 72 1C for 30 seconds,
and a final extension at 72 1C for 3minutes. The PCR products were analyzed by
electrophoresis on 2.5% agarose gels and stained with ethidium bromide, viewed
by ultraviolet light, and photographed. Densitometric analysis was performed by
scanning the bands into Photoshop and performing densitometry with NIH Image
Software.
Plasmids
Firefly luciferase reporter plasmids driven by human MCP-1 promoters (2910/
1bp and 213/1 bp relative to the translational start site), denoted as pMCP-1
(2910) luc and pMCP-1 (213) luc, were constructed by PCR and insertion into pGL3
basic vectors (Promega, Madison, WI) as described previously (Li and Kolattukudy,
1994; Valente et al., 1998; Zhou et al., 1998). p4AP-1-TATA-luc and p4 Spl-
TATA-luc were constructed by inserting four copies of distal AP-1 binding element
(50-TTATCACTCATGG-30, with consensus sequences underlined) or GC-rich Sp1
binding sequences (50-ACTCCGCCCTCT-30) from human MCP-1 promoter in front of
the TATA box upstream of firefly luciferase reporter as described by Philips et al.
(1993). pCMV-ERb expressing full-length human ERb (477 amino acids) was
constructed as described previously (Bhat et al., 1998). Site-specific mutations of
MCP-1 promoter or ERb expression vector were created by multiple rounds of PCR
using appropriate primers with altered bases as described before (Kunkel et al., 1987;
Zhou et al., 1998; Mak et al., 1999; Jakacka et al., 2001). N-terminal deletion
mutants, ERb A/B (), which delete amino acids 1–96 of ERb (Fig 5), were constructed
by PCR using primers containing appropriate truncation as described by Weatherman
and Scanlan (2001).
Transfections
Transient transfections were performed with Effcctene (Qiagcn, Tokyo, Japan) as
described previously (Zellmer et al., 2001). Keratinocytes were plated in 10 cm
dishes and grown to about 60% confluence. Twenty-four hours before the
transfection, the medium was changed to phenol-red-free KBM. Keratinocytes in
KBM were incubated for 6 h with 5mg of pMCP-1 (2910 or 213) luc or p4AP-1-
TATA-luc or p4 Spl -TATA-luc and 1mg of Rous sarcoma virus b-galactosidase
vector (pRSV-Pgal), prcmixed with enhancer, transfection buffer, and Effcctene. The
transfected cells were washed and incubated in KBM for 18 h, and then treated with
E2 for 10minutes prior to the addition of TPA. After 24 h, cell extracts were
prepared and luciferase activities were quantified using the luciferase assay system
(Promega). The same cell extracts were assayed for b-galactosidase activity using
chemiluminescent Galacto-Light kit (Tropix, Bedford, MA). All readings were taken
using a Lumat 9501 luminometer (Berthold, Wildbach, Germany). The results
obtained in each transfection were normalized for (b-galactosidasc activity and
expressed as relative luciferase activity. Human breast carcinoma SKBR3 cells
(ERa- and ERb-negativc) (Dainippon Pharmaceuticals, Osaka, Japan) were
maintained with a 1:1 mixture of Dulbccco’s modified Eagle’s medium (DMEM):-
Ham’s F-12 medium (Invitrogcn, Grand Island, NY) supplemented with 10% fetal
bovine serum. SKBR3 cells were transfected with 5 mg of pMCP-1 (213) luc,
p4AP-1-TATA-luc, or p4 Spl-TATA-luc, and 1mg of pRSV-Pgal, with 1 mg wild-
type or mutated pCMV-ERb or empty pcDNA3 vector using Effcctene in scrum, and
phenol-red-free DMEM:F-12 (1:1). ERb expression vector was similarly transfected
into keratinocytes except for using KBM.
EMSA
The probes used were annealed double-stranded DNA containing distal AP-1
sequences (50-ATTTAACAGCCCACTTATCAC-TCATGGAA-30) or Sp1 binding
sequences (50-CGTGCTGCTTGACT-CCGCCCTCTCTCCC-30) from human MCP-1
promoter, or consensus estrogen response element (50-CAAAGTCAGGTCACAGT-
GACCTGAT-GAAT-30) from vitellogenin A2 gene. The probes were labeled by
incorporation of [32P]dCTP with Klenow DNA polymerase. For gel shift assays,
2–5 pg of nuclear protein extracts were incubated at room temperature for 5minutes
with a mixture containing 6mM HEPES (pH 7.9), 0.4mM ethylenediamine
tetraacetic acid (EDTA), 125mM KC1, 10% glycerol, 0.05 mg per ml poly dI-dC,
1mM dithiothreitol, 2.5mM sodium pyrophosphate, 1mM b-glycerophosphate,
1mM Na3V04, 10mM NaF, 50 mg per ml aprotinin, and 50 mg per ml leupeptin.
Approximately 1 ng labeled probe was added and the reactions were incubated at
room temperature for another 20minutes. In antibody supershift experiments, the
nuclear extracts were preincubated with antibodies against various transcription
factors on ice for 30minutes before the addition of probe. Reactions were then
fractionated on a nondenaturing 5% polyacrylamide gel. The gels were dried and
visualized with phosphorimager (Molecular Dynamics, Sunnyvale, CA).
Western blotting
ER-transfected SKBR3 cells were lyzed in lysis buffer [20mM Tns (pH 8.0), 0.1M
NaCl, 0.5% Nonidct p-40, 1mM EDTA, 1mM phcnylmcthylsulfonyl fluoride (PMSF),
1mg per ml leupeptin, 1mg per ml pepstatin, 1mM dithiothreitol]. The lysatcs were
centrifuged (8000g 5minutes) and the protein concentration of the supcrnatants was
determined by Bio-Rad protein assay reagents (Bio-Rad, Hercules, CA). Twenty
micrograms of total cellular protein was clectrophoresed by sodium dodccyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to a nitrocellulose
membrane. The membrane was blocked and incubated with 1 pg per ml of goat IgG
anti-ERb antibody recognizing the carboxy terminus, and then incubated with
horseradish-pcroxidase-conjugated secondary antibody and developed by enhanced
chemi-luminescence (Amersham, Arlington Heights, IL).
Immunoprecipitation and immunoblotting
Immunoprecipation and immunoblotting were performed as described previously
(Teyssier et al., 2001). ERb-transfccted keratinocytes were preincubated with
108 M E2 for 10minutes, and then incubated with medium alone or with TPA
10nM for 30minutes in the presence or absence of E2. Whole cell extracts were
prepared in lysis buffer [50mM Tris (pH 7.4), 150mM NaCl, 1mM EDTA, 1mM
Na3V04, 20mM b-glyccrol phosphate, 1mM PMSF, 1mg per ml leupeptin, 2mg per
ml aprotinin, 1mg per ml pepstatin, 1% Nonidet p-40, 0.25% deoxycholatc, and
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0.1% SDS]. Extracts were immunoprecipitated with 10 mg per ml of goat polyclonal
anti-ERb antibody (L-20) (Santa Cruz Biotechnology). The immune complexes were
captured on protein G-Sepharose beads (Pharmacia, Piscataway, NJ) for 1 hour at
4 1C. Precipitated proteins were washed with lysis buffer, separated by SDS-PAGE,
and transferred to a nitrocellulose membrane. The membrane was blocked and
incubated with 1 mg per ml of rabbit polyclonal anti-c-Jun (H-79), c-Fos (H-125), or
Sp1 (PEP2) antibodies (Santa Cruz Biotechnology), and then incubated with
horseradish-pcroxidase-conjugated mouse antirabbit IgG (Santa Cruz Biotechnol-
ogy) and developed. Following the analysis of c-Jun, c-Fos, or Sp1, the blots were
stripped and reprobed with anti-ERfi antibody as described above.
RESULTS
E2 inhibited basal and TPA-induced MCP-1 secretion
Keratinocytes constitutivcly secreted MCP-1 (mean±SEM
105±13 pg per ml, n¼5), and TPA 10nM increased the secretion
up to 662±63pg per ml (n¼ 5). E2 concentration-dependently
reduced both constitutive and TPA-induced MCP-1 secretion (Fig 1);
a significant effect of E2 occurred at 1010M, increased concentration-
dependently, and reached a maximum at 108M, which inhibited
constitutive or TPA-induced MCP-1 secretion by 67 or 60%,
respectively. ER antagonist IC1 182,780 alone did not alter constitutive
or TPA-induced MCP-1 secretion in the absence of E2; however, it
counteracted the E2-mediatcd inhibition of constitutive or TPA-induced
MCP-1 secretion (Fig 1), indicating that the effects of E2 may be
mediated via ER. We then examined whether E2 may inhibit
constitutive or TPA-induced MCP-1 mRNA expression in keratinocytes.
E2 inhibited constitutive and TPA-induced MCP-1 mRNA expression
E2 suppressed constitutive or TPA-induced MCP-1 mRNA expres-
sion by 70 or 69% of controls, respectively (Fig 2). These effects of
E2 were counteracted by ICI 182,780. Thus E2 inhibited constitutive
or TPA-induced MCP-1 production at pretranslational level. We
then examined whether E2 may suppress basal or TPA-induced
MCP-1 promoter activity.
E2 inhibits basal and TPA-induced MCP-1 promoter activity
We transiently transfected human MCP-1 promotcr-luciferase
reporter constructs into keratinocytes, and the promoter activity
was assessed by the relative lucifcrase activity of the cell lysates.
Basal promoter activity was confirmed using pMCP-1 (2910) luc, a
construct containing 2910 bp upstream of the translational start site,
and TPA increased the activity 5.3-fold (Fig 3b, uppermost four
columns). E2 reduced basal or TPA-induced activity of wild-type
MCP-1 promoter by 68 or 60% of controls, respectively (Fig 3b,
uppermost four columns), and these effects of E2 were counteracted
by ICI 182 780 (data not shown). A construct containing 213bp
upstream of the translational start site, pMCP-1 (213) luc, was fully
capable of showing basal and TPA-induced MCP-1 promoter
activity and E2-mcdiatcd inhibition (Fig 3b, second four columns),
as well as pMCP-1 (2910) luc. Thus the downstream 213bp clement
appeared to fully direct basal and TPA-induced promoter activity
and E2-mediated inhibition in keratinocytes. Although the MCP-1
50-flanking sequence 2910/2111 bp (distal enhancer region)
contains two nuclear factor kB (NF-kB) binding sites and one AP-1
binding site (Ueda et al., 1994), mutation of these elements did not
abrogate the basal and TPA-induced MCP-1 promoter activities and
E2-mcdiated inhibition (data not shown), indicating that these
elements may be dispensable at least for unstimulated or TPA-
stimulated keratinocytes. Thus further experiments were performed
using pMCP-1 (213) luc.
The 213 bp MCP-1 promoter contains a number of putative
nwcting elements that may contribute to the promoter activity (Fig
3a). We thus examined which of these elements may be responsible
for the inhibition by E2 of the basal or TPA-induced MCP-1
transcription, by using mutated promoters. The mutation of GC-rich
Sp1 binding clement mostly abrogated the basal promoter activity
and the suppression by E2 of the basal activity; however, it retained
the fold induction by TPA and the suppression by E2 of the response
to TPA (Fig 3b, lowermost four columns). This indicates that the Sp1
element may be mainly responsible for the basal promoter activity
and may be involved in E2-induced suppression of the basal
activity. On the other hand, mutation of the distal AP-1 element
abrogated TPA-induced promoter activation but retained the basal
promoter activity (Fig 3b, third four columns), suggesting that the distal
AP-1 element may be mainly responsible for the induction by TPA.
The activity of distal AP-1-mutated promoter was suppressed by E2 in
the presence or absence of TPA (Fig 3b, third four columns), possibly
reflecting its suppression of basal activity and not of the response to
TPA. Mutation of NF-kB or the proximal AP-1 clement did not alter
basal promoter activity or the induction by TPA, and suppressive
effects of E2 on basal and TPA-induced promoter activities (Fig 3b,
fourth and fifth four columns), indicating that these elements may be
dispensable for the basal and TPA-induced promoter activities and
may not be involved in the suppressive effects of E2. These results
suggest that the Sp1 element may be responsible for the basal MCP-1
promoter activity and E2-induced inhibition of the constitutive
transcription whereas the distal AP-1 element may be involved in
TPA-induced promoter activity and E2-mediatcd inhibition of the
response to TPA. We then analyzed if E2 may suppress transcription
through the distal AP-1 or Sp1 element in keratinocytes.
E2 inhibited transcription from the distal AP-1 or Sp1 element
Keratinocytes were transiently transfectcd with plasmid containing
four repeats of distal AP-1 or Sp1 sequences linked to the TATA box
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Figure 1. Concentration dependence for the effects of E2 on constitutive or
TPA-induced MCP-1 secretion in human keratinocytes. Human keratinocytes
were preincubated with indicated concentrations of E2 in the presence or
absence of 106 M ICI 182 780 (ICI) for 10minutes, and then incubated with
medium alone or with 10 nM TPA in the presence or absence of hormones.
After 24 h, the culture supernatants were assayed for MCP-1 secretion. Values
are mean±SD of triplicate cultures. *po0.05 versus control values without
hormones, by one-way anova with Dunnett’s multiple comparison test. The
data shown in the figure are representative of five separate experiments.
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in front of the luciferase reporter, and were incubated with E2 in the
presence or absence of TPA. The transcriptional activity through the
Sp1 clement was constitutively high in keratinocytes, and was not
enhanced by TPA (Fig 4, uppermost four columns). E2 suppressed
the transcriptional activity through Sp1 in the presence or absence
of TPA. The transcriptional activity through distal AP-1 was minimal
in unstimulated keratinocytes, and was enhanced by TPA (Fig 4,
second four columns). E2 suppressed the TPA-induced transcrip-
tional activity through AP-1. ICI 182,780 counteracted the E2-
mcdiatcd inhibition of basal transcriptional activity through Sp1 or
TPA-induced transcriptional activity through AP-1 (data not shown).
E2 inhibited Sp1 or AP-1 transcriptional activities and MCP-1 promoter
activity via ERb
It appeared that ERb mediated E2-induced inhibition of Sp1 or AP-1
transcriptional activities and MCP-1 promoter activity in keratino-
cytes as keratinocytes express ERb but not ERa (Kanda and
Watanabc, 2003a, b). To further test this hypothesis, we examined
if transfection of ERb into ER-ncgative cells may result in
E2-mediated inhibition of these activities. E2 did not inhibit Sp1 or
AP-1 transcriptional activities or MCP-1 promoter activity in cither
the presence or the absence of TPA in ER-ncgative SKBR3 cells
transfectcd with empty pcDNA3 vector (Fig 6a, b, c, d, upper panel,
lanes 1, 2). ERb transfection per se did not alter these activities in the
absence of E2 (Fig 6a, b, c, d, upper panel, lane 3); however, E2
suppressed constitutive Sp1 activity (Fig 6a or MCP-1 promoter
activity (Fig 6b) and TPA-induced AP-1 activity (Fig 6c) or MCP-1
promoter activity (Fig 6d, uppa panel, lanes 4) in ERb-transfected
SKBR3 cells. These findings suggest that suppressive effects of E2 in
SKBR3 cells may be mediated via transfectcd ERb. In keratinocytes
transfectcd with empty pcDNA3, E2 suppressed constitutive Sp1
activity (Fig 6a) or MCP-1 promoter activity (Fig 6b) and TPA-
induced AP-1 activity (Fig 6c) or MCP-1 promoter activity (Fig 6d,
Iowa panel, lanes 2) by 60%-70% of controls, and the inhibitory
effects of E2 were further enhanced by the transfection of ERb, about
90% inhibition versus controls (Fig 6a, b, c, d, lower panel, lane 3).
These findings indicate that E2 may suppress MCP-1 expression via
both endogenous and transfectcd ERb in keratinocytes.
ER is composed of A to F regions: the N-tcrminal A/B region
containing a ligand-independent transcriptional activation function,
the DNA-binding C region, the hinge region D, an E region
containing a ligand-binding domain and ligand-dependent tran-
scriptional activation function (AF-2), and the C-terminal F region
(Fig 5a). We then analyzed which rcgion(s) of ERb may be involved
in the E2-induced suppression of Sp1, AP-1 activities, and MCP-1
promoter activity by transfecting mutant ERb into SKBR3 cells.
Transfection of the A/B-region-delcted ERb into SKBR3 cells did not
reduce constitutive Sp1 activity or MCP-1 promoter activity and
TPA-induced AP-1 activity or MCP-1 promoter activity in the
presence of E2 (Fig 6a, b, c, d, upper panel, lanes 5). This indicates
that the A/B region of ERb may be primarily responsible for the
inhibitory effects of E2. To determine the requirement of ERb DNA-
binding domain (DBD) for E2-mcdiated effects, mutations were
introduced into DBD by substituting alanine residues: ERb E114A/
G115A, which cannot bind to oligonucleotide probe containing
consensus estrogen response clement in EMSA (data not shown;
Jakacka et al., 2001). In ERb E114A/G115A-transfccted cells, E2
showed inhibitory effects (Fig 6a, b, c, d, upper panel, lanes 6), in a
manner similar to those in wild-type ERb-transfected cells (Fig 6a, b,
c, d, upper panel, lanes 4), indicating that ERb DBD may be
dispensable for E2-induced suppression of Sp1 and AP-1 activities,
or MCP-1 promoter activities. AF-2 of ERb plays in important role in
the interaction with transcriptional coactivators (Mak et al., 1999),
and two different point mutations (ERP L437A/E440A) were
introduced into ERb helix 12 of the AF-2 surface, which disrupts
interactions with pl60 family coactivators and E2-induced transcrip-
tion from estrogen response element (Mak et al., 1999). In ERb
L437A/E440A-transfected cells, E2 did not suppress Sp1 or AP-1
activity or MCP-1 promoter activities (Fig 6a, b, c, d, upper panel,
lanes 7), indicating that an intact AF-2 surface may be required for
the transcriptional repression by E2.
E2 did not alter DNA binding of Sp1 or AP-1
We then examined if E2 may suppress DNA binding of transcription
factors at the Sp1 or AP-1 element. As inhibitory effects of E2 on Sp1
and AP-1 activities were most remarkably seen in ERb-transfected
kcratinocytcs (Fig 6), nuclear extracts from these cells were used for
EMSA. Nuclear extracts from ERb-transfectcd keratinocytes without
TPA stimulation formed a DNA-protcin complex with the Sp1-
elemcnt-containing probe (Fig 7a, lane 2), and the amount of the
complex was not reduced by E2 (Fig 7a, lane 3). Anti-Spl antibody
(Fig 7a, lane 4) but not anti-Sp2, Sp3, Sp4, or AP-2 antibodies (data
not shown) supershifted the complex with the Sp1 probe, indicating
Figure 2. The effects of E2 on constitutive or TPA-induced MCP-l mRNA
expression in human keratinocytes. Keratinocytes were preincubated with
108 M E2 alone or together with 106 M ICI 182 780 (ICI) for 10 min, and then
incubated with medium alone or TPA 10nM in the presence or absence of
hormones for another 6 h. UNA was isolated, and RT-PCR was performed.
The intensity of the band for MCP-1 was corrected to that for GAPDH. The
lower graph shows the corrected intensities relative to that in control cells
cultured with medium alone (set as 1.0). The results shown in the figure are
representative of five separate experiments.
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the presence of Sp1 in the complex. The amount of DNA-protcin
complex with Sp1 probe was not altered by TPA in the presence or
absence of E2 (Fig 7a, lanes 7, 8). The nuclear extracts from ERb-
transfected keratinocytes without TPA stimulation formed a small
amount of DNA-protein complex with distal AP-1-containing probe
(Fig 7b, lane 2), and the amount was increased by TPA (Fig 7b, lane
4). The addition of E2 did not reduce the amount of basal or TPA-
induced complexes with AP-1 probe (Fig 7b, lanes 3, 5). Anti-c-Jun
and c-Fos antibodies (Fig 7b, lanes 6, 7) but not anti-JunB, JunD,
FosB, Fra-1, or Fra-2 antibodies (data not shown) supershifted the
DNA-protcin complex with AP-1 probe, indicating that the complex
may be composed of c-Fos/c-Jun heterodimers. These results
indicate that E2 may inhibit the transactivation ability of Sp1 or
AP-1 without inhibiting their DNA binding. We then examined the
presence of ERb in the Sp1 or AP-1 complex with DNA by using
anti-ERP antibody, which supershifted ERb bound to estrogen
response element (Fig 7c). Faint but significant supershifted bands
by anti-ERb (Fig 7a, lane 5; Fig 7b, lane 8) were obtained with the
Sp1 or AP-1 complex from nuclear extracts treated with E2, but the
supershifts were not obtained from nuclear extracts without E2
treatment (Fig 7a, lane 6; Fig 7b, lane 9). This indicates the presence
of ERb in the protcin-DNA complex and E2-dcpendcnt interaction
of ERb with Sp1 or AP-1. The supershiftcd bands by anti-ERP
antibody were not obtained in nuclear extracts from keratinocytes
KANDA AND WATANABE
Figure 3. The effects of E2 on constitutive or TPA-induced activities of wild-type or mutated MCP-1 promoters in human keratinocytes. (a) Schematic
representation of human MCP-1 promoter. The locations of cis elements are shown with their sequences, and substituted bases for mutation are shown in italic.
The nucleotide positions are relative to the translational start site, (b) Keratinocytes were transiently transfected with wild-type (WT) or mutated human MCP-l
promoter linked to luciferase reporter together with b-galactosidasc vector, prcincubated with or without 108 M E2 for 10minutes, and then incubated with
medium alone or with TPA 10 nM for 24 h. Relative luciferase activities normalized to b-galactosidase activities are shown. The data are mean±SEM (n¼ 4).
Values at the right indicate the fold induction versus basal promoter activity. *po0.05 versus control values; wpo0.05 versus values with TPA alone, by one-way
anova with Scheffc’s multiple comparison test.
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without ERb transfection (data not shown), possibly because the
amount of endogenous ERb associated with Sp1 or AP-1 may be
lower and thus undetectable by the antibody, and/or the epitope
for the antibody on ERb may be masked by the interaction with Sp1
or AP-1.
The E2-dependent association of ERb with Sp1 or AP-1 was
further investigated by coimmunoprecipitation studies. Whole cell
extracts from ERb-transfected keratinocytes were immunoprecipi-
tated with anti-ERb antibody, and then immunoblotted by anti-Sp1,
c-Jun, or c-Fos antibodies. Sp1 protein was detected in anti-ERb
immunoprecipitatcs from ERb-transfected keratinocytes cultured in
the presence but not in the absence of E2 (Fig 8a). Sp1 was also
detected in anti-ERP immunoprccipitates from ERfi-transfected
keratinocytes treated with TPA plus E2 but not with TPA alone
(data not shown). c-Jun and c-Fos proteins were detected in anti-ERb
immunoprecipitatcs from ERb-transfectcd keratinocytes treated with
TPA in the presence but not in the absence of E2 (Fig 8b). c-Jun and
c-Fos were not detected in anti-ERP immunoprecipitatcs from ERb-
transfectcd keratinocytes treated with E2 alone without TPA (data
not shown). These results demonstrate that ERb could interact with
Sp1 or AP-1 proteins in an E2-depcndcnt manner.
DISCUSSION
This study demonstrated that E2 inhibited constitutive and TPA-
induced MCP-1 transcription in human neonatal foreskin keratino-
cytes by inhibiting transcriptional activity of Sp1 and AP-1,
respectively. These effects of E2 appeared to be mediated via ERb.
We also preliminarily found that keratinocytes from le-sional skin of
psoriasis showed enhanced basal and TPA-induced MCP-1 secre-
tion and mRNA expression compared to normal foreskin keratino-
cytes, and that the MCP-1 expression in psoriatic keratinocytes was
suppressed by E2 as well as normal foreskin keratinocytes (data not
shown). The element conferring response to TPA on MCP-1
promotet appeared to differ depending on cell type: the AP-1
binding site (157/151 bp relative to the translational start site) in
keratinocytes and glioblastoma U138-MG (Li and Kolattukudy,
1994), and the far upstream NF-kB clement (2612/2603bp
relative to the transcriptional start site, corresponding to 2672/
2663bp relative to the translational start site) in glioblastoma
A172 and fibrosarcoma HT1080 (Ueda et al., 1994). Such
discrepancy may possibly be due to the cell type specificity in the
relative amounts or activities of transcription factors or the activities
of signaling molecules regulating transcription factor activities. At
least in human keratinocytes, the far upstream NF-kB site may not
be involved in TPA-induced MCP-1 transcription and E2-mcdiatcd
inhibition of the response to TPA (Fig 3). This element may act as
the target for the inhibitory effects of E2 in the other cell types,
however; it was required for IL-la-induced MCP-1 transcription in
mammary carcinoma MCF-7 and the transcription was inhibited by
E2 partially via inhibiting the DNA binding of NF-kB at this element
(Inadera et al., 2000). As IL-1a and IL-1b, which may potentiate NF-
kB activity, did not induce MCP-1 production in human kcratino-
cytes (our unpublished observation), we should further examine if
other stimuli such as lipopo-lysaccharidc may induce MCP-1
transcription through this NF-kB clement (2672/2663 bp) in
keratinocytes and if E2 may suppress the NF-kB-dependent MCP-1
transcription.
Previous studies reported that E2 inhibited Sp1 or AP-1-mediatcd
gene expression via ERb (An et al., 1999; Zou et al., 1999; Saville
et al., 2000; Sawada et al., 2000; Maruyama et al., 2001; Safe,
2001). In kcratinocytes, the A/B region and intact AF-2 structure of
ERb were required for E2-mcdiatcd inhibition of Sp1 or AP-l -
mediated transcription (Fig 6). On the other hand, mutation of DBD
in ERb did not disrupt the inhibitory effects of E2 (Fig 6), indicating
that the effects of E2 may not be mediated by ER–DNA interaction
but by the interaction of ER and Sp1 or AP-1 proteins. The results in
coimmunoprecipitation assays (Fig 8) indicate that ERb may interact
with Sp1 or AP-1 in the presence of E2. As an intact coactivator
interaction surface of AF-2 was required for the transcriptional
repression by E2 (Fig 6), the AF-2 surface of E2-bound ERb may
interact with the following transcriptional coactivators tethered to
Figure 4. The effect of E2 on Sp1 or AP-1 transactivation ability.
Keratinocytes were transiently transfectcd with luciferase reporter plasmids
driven by Sp1 or AP-1 in front of the TATA box or enhancerless TATA-
luciferase vector, together with b-galactosidasc vector. The cells were prein-
cubated with or without 108M E2, and then incubated with medium alone or
TPA 10 nM in the presence or absence of E2 for 24 h. The results arc shown as
relative luciferase activities normalized tor b-galactosidase activities, and
represent mean±SEM (n¼ 4). Values at the right indicate the fold induction
versus basal activity. *po0.05 versus control values with medium alone;
wpo0.05 versus values with TPA alone, by one-way anova with Schcffe’s
multiple comparison test.
Figure 5. Schemes for wild-type or mutant ERbs (a) and western blot analysis
of the ERb-transfected SKBR3 cell extracts (b) using anti-ERb antibody
specific to the carboxy terminus. Numbers below each construct scheme
denote amino acid numbers (a).
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Sp1 or AP-l on DNA: p300/CREB-binding protein (Kamei et al.,
1996; Naar et al., 1998), SNURF (Saville et al., 2002), pl60 family
GRIP1, or novel coactivator CAPER (Teyssier et al., 2001; Jung
et al., 2002). E2-bound ERb may interact with AP-1 or Sp1/
coactivator complex bound onto DNA and act as a transcriptional
coreprcssor; possibly the A/B region of ERb may inhibit the
interaction of the above-mentioned complex with general transcrip-
tional components like TATA-associatcd factors and/or inhibit the
release of transcriptional corepressors.
ER contains two dimerization domains, one in DBD, which is
involved in ligand-independent dimerization, and the other in the
ligand-binding domain mediating ligand-dependent dimerization
(Chen et al., 1999). The ERfi-mediatcd suppression of Sp1 or AP-1
activity was E2-dependent and DBD was dispensable for the
suppression (Fig 6). Thus E2-bound ERb may dimcrize through the
dimerization domain in the ligand-binding domain and such dimers
may interact with Sp1 or AP-1/coactivator complex. Alternatively,
dimerization may not be required for the suppression of Sp1 or AP-
1-mediated transcription by E2-bound Ellp as DBD was dispensable
for the suppression and thus E2-bound ERb may not directly bind to
DNA. Sawada et al (2002) also reported that ER dimerization
inhibitor YP537 did not reverse the inhibitory effect of E2 on AP-1
transcriptional activity in dopaminergic neurons.
Our results suggest that E2 may inhibit MCP-1 production in the
skin in the unstimulated state or under AP-1-driving stimuli such as
oxidative stress, ultraviolet irradiation, bacterial superanti-gen, or
hapten (Miyazaki et al., 2000). The actions of E2 may differ on MCP-
1 induction by proinflammatory cytokines such as IFN-a or TNF-a,
however, in comparison to theTPA-induced system. As these
cytokines, either alone or together, can induce MCP-1 production
in kcratinocytes (Barker et al., 1991b; Li et al., 2000; Giustizieri
et al., 2001), further studies should examine if E2 may suppress IFN-
a and/or TNF-a-induced MCP-1 production in keratinocytes. In
addition to MCP-1, E2 inhibited the production ot RANTES, another
chemokine attracting macrophages, in human kcratinocytes (Kanda
and Watanabc, 2003b). Taken together, E2 may be therapeutically
useful for the treatment of macro-phagc-involving inflammatory
skin diseases like psoriasis. Estrogen may have another antipsoriatic
effect; estrogen inhibits the induction of epidermal ornithine
decarboxylase, required for DNA replication, indicating that
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Figure 6. The effects of E2 on Sp1 (a) or AP-1 (c) transcriptional activities or MCP-1 promoter activity (b, d) in wild-type or mutant ERb-transfected SKBR3 cells and
keratinocytes. SKBR3 cells or keratinocytes were transfected with p4 X Sp1-TATA-luc (a), p4 X AlM-TATA-luc (c), or pMCP-1 (213) luc (b, d), and pRSV-bgal, together with
wild-type or mutant pCMV-ERb or empty pcDNA3 vector. The cells were pretreated with or without 108M E2 for 10minutes, and then treated with medium alone (a, b)
or TPA 10nM (c, d) in the presence or absence of E2 for 24h. The results are shown as relative luciferasc activities normalized for b-galactosidasc activities, and represent
mean± SEM (n¼4). Open columns show the values without E2 incubation whereas dotted columns show the values with E2 incubation. AP-1 transcriptional activity
with medium alone was mean±SEM 4.1±0.9 in empty-pcDNA3-transfected SKBR3 cells and 3.8±0.8 in empty-pcDNA3-transfected keratinocytes, respectively.
*po0.05 versus control values of empty-vector-transfectcd cells without E2 treatment; wpo0.05 versus values of empty-vector-transfected cells with E2 treatment, by one-
way anova with Scheffe’s multiple comparison test.
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estrogen may inhibit keratino-cyte hypcrprolifcration occurring in
psoriasis (Arnold et al., 1993). The effects of estrogen on skin in vivo
have recently been studied; topical or systemic estrogen treatment is
known to prevent skin aging whereas it may cause skin hyperpig-
mentation (Sator et al., 2001; Shah and Maibach, 2001). Ther-
apeutic effects of estrogen on psoriasis, however, have hardly been
studied in vivo. Only one study reported that combinational use of
estrogen with cor-ticosteroid reduced the dose of the latter drug
required for a psoriatic patient, indicating the synergistic effect of
estrogen (Spangler et al., 1969). Additional insights into the
therapeutic effects of estrogen on psoriasis may be provided by
prospective studies of postmenopausal patients with hormone
replacement therapy or patients taking fertility drugs or oral
contraceptives.
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